Short Course: Immunotherapy in myeloma

In recent years, advances in the field of immuno-oncology have led to a greater understanding of how the body’s immune system can be harnessed to improve outcomes for myeloma patients.

Some of the most promising areas of research and emerging immunotherapies include specific antibodies that target tumour and immune cells, small molecule immunomodulatory drugs, tumour-specific T-cell directed therapies, immune checkpoint regulators, vaccination strategies, and oncolytic virotherapy.

With a number of immunotherapies now approved in myeloma, as well as several undergoing clinical development, it is important that clinicians are informed about the immunotherapies that are currently available, what trials are ongoing and which emerging immunotherapeutic areas show most promise.

By staying up to date with the latest research and practice in the rapidly expanding field of immunotherapy in myeloma, haematologists can help patients achieve the best possible outcomes.

Learning objectives

After successfully completing this course, you should be better able to:

• Understand why the immune system provides a useful target for novel drug development in myeloma
• Distinguish between the different mechanisms of action of emerging immunotherapeutic approaches
• Discuss the current state of immunotherapy in myeloma

CPD Information

We recommend you go through each module in numerical order. All modules and assessments must be completed and a final score of 70% must be achieved to receive your CPD credits. Your certificate will be issued on completion of the evaluation survey, your feedback will help us improve future courses.
Total CPD hours: 5

Faculty

At a Glance: The immune system and immunotherapy in myeloma

A handy two-page reference guide covering the key learning points from this short course.

Download now >

Immunotherapy Modules